Surface expression of the HLA-class I molecules and the ligands for DNAM-1 and NKG2D triggering receptors in AMLs belonging to different FAB subtypes
. | . | . | DNAM-1 ligands . | . | NKG2D ligands . | |
|---|---|---|---|---|---|---|
| Patient no. . | FAB . | HLA-I . | Nectin-2 . | PVR . | MICA/B and ULBPs . | |
| ML1 | M0 | 500* | 19 | 5 | ULBP1 (5)† | |
| ML2 | M1 | 200 | 12 | 4 | ULBP3 (2) | |
| ML3 | M1 | 125 | 8 | 8 | NEG | |
| ML4 | M1 | 100 | 5 | 3 | NEG | |
| ML5 | M1 | 165 | 16 | 11 | NEG | |
| ML6 | M1 | 120 | 15 | 6 | NEG | |
| ML7 | M1 | 123 | 1 | 1 | NEG | |
| ML8 | M1 | 152 | 20 | 3 | ND | |
| ML9 | M2 | 33 | 4 | 4 | ULBP1 (2) | |
| ML10 | M2 | 190 | 12 | 9 | NEG | |
| ML11 | M2 | 675 | 6 | 5 | ULBP3 (2) | |
| ML12 | M2 | 68 | 9 | 7 | NEG | |
| ML13 | M3 | 67 | 1 | 5 | NEG | |
| ML14 | M3 | 81 | 5 | 9 | NEG | |
| ML15 | M4 | 192 | 4 | 17 | ULBP2 (3) ULBP3 (2) | |
| ML16 | M4 | 57 | 3 | 4 | NEG | |
| ML17 | M4 | 122 | 14 | 10 | NEG | |
| ML18 | M5a | 278 | 31 | 6 | ULBP1 (8) ULBP3 (5) | |
| ML19 | M5a | 148 | 4 | 6 | NEG | |
| ML20 | M5b | 111 | 3 | 3 | NEG | |
| ML21 | M5b | 167 | 5 | 6 | ND | |
| ML22 | M5b | 92 | 4 | 5 | ULBP1 (2) | |
| ML23 | M7 | 275 | 26 | 7 | NEG | |
| ML24 | M7 | 350 | 6 | 2 | NEG | |
| ML25 | CML | ND | 6 | 10 | NEG | |
. | . | . | DNAM-1 ligands . | . | NKG2D ligands . | |
|---|---|---|---|---|---|---|
| Patient no. . | FAB . | HLA-I . | Nectin-2 . | PVR . | MICA/B and ULBPs . | |
| ML1 | M0 | 500* | 19 | 5 | ULBP1 (5)† | |
| ML2 | M1 | 200 | 12 | 4 | ULBP3 (2) | |
| ML3 | M1 | 125 | 8 | 8 | NEG | |
| ML4 | M1 | 100 | 5 | 3 | NEG | |
| ML5 | M1 | 165 | 16 | 11 | NEG | |
| ML6 | M1 | 120 | 15 | 6 | NEG | |
| ML7 | M1 | 123 | 1 | 1 | NEG | |
| ML8 | M1 | 152 | 20 | 3 | ND | |
| ML9 | M2 | 33 | 4 | 4 | ULBP1 (2) | |
| ML10 | M2 | 190 | 12 | 9 | NEG | |
| ML11 | M2 | 675 | 6 | 5 | ULBP3 (2) | |
| ML12 | M2 | 68 | 9 | 7 | NEG | |
| ML13 | M3 | 67 | 1 | 5 | NEG | |
| ML14 | M3 | 81 | 5 | 9 | NEG | |
| ML15 | M4 | 192 | 4 | 17 | ULBP2 (3) ULBP3 (2) | |
| ML16 | M4 | 57 | 3 | 4 | NEG | |
| ML17 | M4 | 122 | 14 | 10 | NEG | |
| ML18 | M5a | 278 | 31 | 6 | ULBP1 (8) ULBP3 (5) | |
| ML19 | M5a | 148 | 4 | 6 | NEG | |
| ML20 | M5b | 111 | 3 | 3 | NEG | |
| ML21 | M5b | 167 | 5 | 6 | ND | |
| ML22 | M5b | 92 | 4 | 5 | ULBP1 (2) | |
| ML23 | M7 | 275 | 26 | 7 | NEG | |
| ML24 | M7 | 350 | 6 | 2 | NEG | |
| ML25 | CML | ND | 6 | 10 | NEG | |
ND indicates not determined.
Values indicate the MRFI (see “Materials and methods”). In the same experimental conditions, MRFI of HLA-I analyzed in PBMCs derived from various healthy donors ranged between 200 and 500
Only the expressed molecules among MICA and ULBP1-4 are indicated and the values within parentheses represent the MRFI